In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $12.93 in the prior trading day, Benitec Biopharma Inc (NASDAQ: BNTC) closed at $13.02, up 0.66%. In other words, the price has increased by $0.66 from its previous closing price. On the day, 0.22 million shares were traded. BNTC stock price reached its highest trading level at $13.09 during the session, while it also had its lowest trading level at $12.65.
Ratios:
Our goal is to gain a better understanding of BNTC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 46.95 and its Current Ratio is at 46.95. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On December 16, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $28.
On December 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $30.Robert W. Baird initiated its Outperform rating on December 13, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 07 ’25 when SUVRETTA CAPITAL MANAGEMENT, L bought 1,481,481 shares for $13.50 per share. The transaction valued at 19,999,994 led to the insider holds 9,538,175 shares of the business.
SUVRETTA CAPITAL MANAGEMENT, L bought 16,497 shares of BNTC for $211,736 on Mar 31 ’25. The Director now owns 8,807,805 shares after completing the transaction at $12.83 per share. On Mar 26 ’25, another insider, SUVRETTA CAPITAL MANAGEMENT, L, who serves as the Director of the company, bought 900,000 shares for $13.00 each. As a result, the insider paid 11,700,000 and bolstered with 8,793,245 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BNTC now has a Market Capitalization of 440716864 and an Enterprise Value of 347054880.
Stock Price History:
The Beta on a monthly basis for BNTC is 0.22, which has changed by 0.28146684 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, BNTC has reached a high of $17.15, while it has fallen to a 52-week low of $9.49. The 50-Day Moving Average of the stock is -9.34%, while the 200-Day Moving Average is calculated to be -3.79%.
Shares Statistics:
The stock has traded on average 136.52K shares per day over the past 3-months and 202780 shares per day over the last 10 days, according to various share statistics. A total of 33.86M shares are outstanding, with a floating share count of 32.67M. Insiders hold about 3.53% of the company’s shares, while institutions hold 76.37% stake in the company. Shares short for BNTC as of 1763078400 were 1412511 with a Short Ratio of 10.35, compared to 1760486400 on 1127047. Therefore, it implies a Short% of Shares Outstanding of 1412511 and a Short% of Float of 7.470000000000001.
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of Benitec Biopharma Inc (BNTC) in the stock market.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.2 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.94 and -$1.06 for the fiscal current year, implying an average EPS of -$1.01. EPS for the following year is -$1.36, with 6.0 analysts recommending between $0.31 and -$2.67.
